Toutes les études
RecrutementConfirmatoire thérapeutique (Phase III)Interventionnel

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)

This important study is looking into a new inhaled medicine called saralutinib for a serious lung condition called pulmonary arterial hypertension (PAH). PAH makes it hard for your heart to pump blood to your lungs, causing breathlessness and tiredness. In this study, some people will get the new medicine, and others will get an identical-looking dummy inhaler (placebo). No one, not even the doctors, will know who is getting what until the study ends. The main goal is to see if the new medicine helps people walk further in six minutes after 24 weeks. The study also checks for other signs of improvement and any side effects to understand if this new treatment is safe and effective.

En un coup d'œil

Statut
Recrutement
Phase
Confirmatoire thérapeutique (Phase III)
Sponsor
GB002 Inc.
Objectif d'inscription
169
Démarrer
23 nov. 2023

De quoi parle cette étude ?

This study is about an investigational medicine called saralutinib, which is given as an inhaled powder. It's being tested for a serious condition called Pulmonary Arterial Hypertension (PAH). PAH is a rare disease where the blood vessels in your lungs become narrow, making it difficult for your heart to pump blood through them. This can lead to symptoms like shortness of breath, tiredness, and chest pain. Treating PAH is important because it can get worse over time.

The study is designed to carefully compare saralutinib with a 'placebo.' A placebo looks exactly like the real medicine but doesn't contain any active drug. Giving some people the new medicine and others the placebo helps doctors determine if any changes or improvements are truly due to the medicine itself, rather than other factors. This way, we can be sure about the medicine's effects. Neither you nor your doctor will know if you are receiving the active medicine or the placebo until the study is over.

The main thing researchers want to find out is whether saralutinib helps people with PAH improve their ability to walk. They will measure this by seeing how far people can walk in six minutes at the start of the study and again after 24 weeks. They'll also look at other important markers of health, like how long it takes for a person's condition to worsen, how many people show overall clinical improvement, and changes in certain blood tests. They will also carefully record any side effects to understand the medicine's safety. This type of study, called a Phase 3 study, is usually the last step before a new medicine might become available to the public.

Points clés

  • Tests a new inhaled medicine (saralutinib) for PAH.
  • Compares the new medicine to a dummy inhaler (placebo).
  • Focuses on improving walking ability and overall health.
  • Involves regular clinic visits and using an inhaler.
  • Aims to check both how well it works and its safety.

Qui peut être éligible ?

To be considered for this study, you must be at least 18 years old. Both men and women are welcome to take part. Since the study focuses on Pulmonary Arterial Hypertension (PAH), you would need to have a confirmed diagnosis of this condition.

There might be other specific health requirements or conditions that would mean you can't join the study. These could include certain medications you're taking, other medical problems you have, or specific results from medical tests. These detailed rules help make sure the study is safe for everyone involved and that the results are clear.

It's important to discuss your full medical history with the study doctor and team. They will go through all the criteria to determine if this study is suitable for you. They'll also ensure you understand everything before you decide to participate.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous 18 ans ou plus ?
  2. Do you have a diagnosis of Pulmonary Arterial Hypertension (PAH)?
  3. Êtes-vous en mesure d'assister à des rendez-vous réguliers à la clinique ?
  4. Are you willing to use an inhaler as part of the study?
  5. Are you able to participate in a six-minute walk test?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part in this study, you would primarily be using an inhaler device to take your study medicine (either saralutinib or the placebo) as directed. This would be done at home. You will have regular visits to the study clinic or hospital. These visits will involve various assessments, such as physical examinations, blood tests, and heart and lung function tests. A key assessment is the 'six-minute walk test,' where you'll walk as far as you can in six minutes, as this is how the study measures how well the medicine is working.

You will receive a supply of the study medicine (inhaler capsules) at each visit. You'll also need to keep track of any symptoms or side effects you experience. The study team will provide you with information on how to do this. There will be specific follow-up appointments to monitor your health and collect data. The overall duration of your active participation in receiving the study drug and undergoing these main assessments will be 24 weeks, though there might be some follow-up calls or visits after that period.

Risques et avantages potentiels

Taking part in a clinical study can offer potential benefits, such as access to a new treatment that isn't widely available. While saralutinib may help improve your walking ability and overall health, there's also a chance it might not work for you, or you might receive the placebo. All medicines, including experimental ones, carry potential risks and side effects. The study team will carefully monitor you for any unwanted effects, like adverse reactions, which will be fully explained to you before you join. Remember, your participation is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (16)

Certains emplacements de site sont approximatifs. Nous améliorons cela — veuillez vérifier avec l'équipe d'essai avant de vous déplacer.
  • —
    Non vérifié
    Espagne
  • —
    Non vérifié
    Lituanie
  • —
    Non vérifié
    Grèce
  • —
    Non vérifié
    France
  • —
    Non vérifié
    Danemark
  • —
    Non vérifié
    Allemagne
  • —
    Non vérifié
    Belgique
  • —
    Non vérifié
    Portugal
  • —
    Non vérifié
    Tchéquie
  • —
    Non vérifié
    Lettonie
  • —
    Non vérifié
    Pays-Bas
  • —
    Non vérifié
    Pologne

Questions fréquentes

What is Pulmonary Arterial Hypertension (PAH)?

PAH is a condition where the blood vessels in your lungs become narrowed, making it harder for your heart to pump blood, causing shortness of breath and tiredness.

Qu'est-ce qu'un 'placebo' ?

A placebo is a dummy inhaler that looks exactly like the real medicine but contains no active drug. It helps researchers see if the real medicine is effective.

What is the 'six-minute walk test'?

It's a simple test where you walk as far as you can in six minutes. It helps doctors measure how well you can exercise and how your condition is improving.

Will I know if I'm getting the new medicine or the placebo?

No, this is a 'blinded' study, so neither you nor your doctor will know until the study is over. This ensures fair and accurate results.

Combien de temps dure l'étude ?

The main part of the study where you get the medicine and have tests will last for 24 weeks (about 6 months).

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Stud… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.